ADMA Biologics Inc (ADMA)

Debt-to-capital ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	101,326	131,074	130,847	130,594	142,026	140,312	144,301	142,833	141,366	139,811	138,423	94,866	94,363	93,877	93,413	92,969	97,044	96,574	96,129	68,291
Total stockholders’ equity	US$ in thousands	231,890	188,269	153,706	135,206	151,437	146,762	145,655	151,974	100,385	114,401	126,933	141,173	102,780	111,594	112,504	88,249	71,376	76,879	96,336	26,193
Debt-to-capital ratio		0.30	0.41	0.46	0.49	0.48	0.49	0.50	0.48	0.58	0.55	0.52	0.40	0.48	0.46	0.45	0.51	0.58	0.56	0.50	0.72

September 30, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $101,326K ÷ ($101,326K + $231,890K)
= 0.30

The debt-to-capital ratio of ADMA Biologics Inc has shown some fluctuations over the past few quarters. The ratio was at its lowest at 0.30 in September 2024 and has ranged from 0.30 to 0.72 over the past five years. Generally, a lower debt-to-capital ratio indicates a lower reliance on debt to finance operations and indicates a stronger financial position. ADMA Biologics Inc's ratio has been relatively stable around 0.40 to 0.50 in recent quarters, suggesting a moderate level of debt in relation to its total capital. It is important for the company to monitor this ratio consistently to ensure it maintains a healthy balance between debt and equity financing.